Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma.

导出 OA

翻译打印收藏纠错

第一作者： Tom,van Meerten

第一单位： Department of Haematology, University Medical Center Groningen Groningen, The Netherlands.

作者： Tom,van Meerten ^[1] ; John,Kuruvilla ^[2] ; Kevin W,Song ^[3] ; Catherine,Thieblemont ^[4] ; Monique C,Minnema ^[5] ; Edouard,Forcade ^[6] ; Sophie,De Guibert ^[7] ; Marie José,Kersten ^[8] ; Pim Gnj,Mutsaers ^[9] ; Martin,Wermke ^[10] ; Yan,Zheng ^[11] ; Allen,Xue ^[11] ; Joshua N,Winters ^[11] ; Jenny,Nater ^[11] ; Rhine R,Shen ^[11] ; Clare,Spooner ^[11] ; Frank,Neumann ^[11] ; Jenny J,Kim ^[11] ; Max S,Topp ^[12]

作者单位： Department of Haematology, University Medical Center Groningen Groningen, The Netherlands. ^[1] Princess Margaret Cancer Centre Toronto, ON, Canada. ^[2] Vancouver General Hospital, BC Cancer, The University of British Columbia Vancouver, BC, Canada. ^[3] Assistance Publique-Hôpitaux de Paris, Hemato-Oncology, Hôpital Saint-Louis, Paris University Paris, France. ^[4] Department of Haematology, University Medical Center Utrecht Utrecht, The Netherlands. ^[5] CHU Bordeaux, Service d'Hematologie et Thérapie Cellulaire Bordeaux, France. ^[6] Hématologie Clinique, CHU Rennes Rennes, France. ^[7] Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam Amsterdam, The Netherlands. ^[8] Department of Hematology, Erasmus University Medical Center Rotterdam, The Netherlands. ^[9] TU Dresden Medizinische Fakultät Carl-Gustav Carus, NCT/UCC Early Clinical Trial Unit/Medizinische Klinik I Dresden, Germany. ^[10] Kite, a Gilead Company Santa Monica, CA, USA. ^[11] Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg Würzburg, Germany. ^[12]

关键词 Large B-cell lymphoma axi-cel chimeric antigen receptor T cell cytokine release syndrome debulking neurotoxicity

DOI 10.62347/LLXR8002

PMID 39005691

发布时间 2024-07-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交